交易中 09-16 15:48:04 美东时间
-15.060
-17.74%
BioMarin Pharmaceutical (NASDAQ:BMRN) is down ~17% Monday following positive data from an Ascendis Pharma (ASND) achondroplasia candidate that could challenge the former's Voxzogo. Data from the pivot...
48分钟前
Goldman Sachs analysts listed 25 mid-cap stocks that have quality and growth attributes and that trade at attractive valuations relative to their history. Each of these companies trade at a next-12-mo...
09-11 23:32
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-09 18:41
BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth.
09-05 21:51
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 14 analysts ...
09-05 21:00
Truist Securities analyst Robyn Karnauskas maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $140 to $118.
09-05 20:12
Barclays analyst Gena Wang maintained a Buy rating on BioMarin Pharmaceutical (...
09-05 17:16
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow breakeven target. Analysts remain optimistic about Yorvipath's market potential despite challenges.
09-05 05:02
BioMarin Pharmaceutical (NASDAQ:BMRN) introduced its longer-term outlook and plans to implement a $500M cost transformation program at its investor day event today. The New York-based pharma has under...
09-05 02:07
NEW YORK, Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York. The event begins at 10:30 a.m. Eastern Time and can be acce...
09-04 19:30